Navigation Links
Reportlinker Adds Key Companies: HIV - Companies Co-Operate and Co-Formulate to Stay Competitive in a Tight HIV Market
Date:6/27/2011

NEW YORK, June 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Key Companies: HIV - Companies co-operate and co-formulate to stay competitive in a tight HIV market

http://www.reportlinker.com/p0564410/Key-Companies-HIV---Companies-co-operate-and-co-formulate-to-stay-competitive-in-a-tight-HIV-market.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Introduction

HIV across the seven major markets is largely dominated by two companies: Gilead Sciences and ViiV Healthcare. The growing dominance of convenient one-pill once-daily regimens will increasingly pressure companies to collaborate and co-formulate their marketed and/or pipeline HIV drugs into fixed dose combinations (FDCs) to remain successful in a tight HIV market.

Features and benefits

* In-depth discussion of portfolios and strategies of key HIV companies.

* Discussion of future strategic opportunities to achieve success in a crowded HIV market.

* Review of corporate strategies in HIV.

Highlights

With Gilead and ViiV Healthcare clearly dominating the HIV market, the remaining companies active in the field have much smaller HIV portfolios. An emerging HIV treatment trend towards nuc-sparing regimens offers opportunities for smaller players to form new vertical collaborations and to diversify the HIV field.

With its blockbuster products Truvada (tenofovir disoproxil fumarate/emtricitabine) and Atripla (tenofovir disoproxil fumarate/emtricitabine/efavirenz), Gilead Sciences is the current HIV market leader in the seven major markets. Its strong late-stage pipeline will help Gilead to defend this position in the short- to mid-term future.

ViiV Healthcare's currently marketed HIV portfolio is diverse but includes several older drugs. However, of all companies involved in the HIV field, ViiV has by far the richest and most diverse HIV pipeline, offering plenty of opportunity to challenge Gilead's current position as HIV market leader in the mid-to long-term future.

Your key questions answered

* Learn about the key HIV companies active in the seven major markets and their portfolios of marketed and pipeline HIV drugs.

* Recognize trends in HIV drug development and learn how companies can respond to future opportunities and challenges in the field.

* Understand corporate strategies for the life-cycle management of HIV drugs in the seven major markets.

Executive Summary

Strategic scoping and focus

Datamonitor key findings

Related reports

OVERVIEW

Catalyst

Summary

COMPANY STRATEGIES

Strategic overview

Trends in corporate strategy

Co-operating and co-formulating are the key strategies to claim HIV market share

Nuc-sparing regimens could diversify the HIV field

Greater choice among different HIV regimens could pave the way towards individualized treatment

Smaller companies are betting on novel delivery methods and other innovative approaches for HIV treatment

Recent strategic partnerships/deals

Gilead Sciences/Bristol-Myers Squibb's joint venture for Atripla kick-started a new era in HIV development

In 2009, GlaxoSmithKline and Pfizer formed specialist HIV company ViiV Healthcare

GlaxoSmithKline/ViiV team up with Shionogi to gain competitive edge in HIV

Gilead and Tibotec/Johnson & Johnson join forces to develop Truvada/rilpivirine

Merck & Co. and Schering-Plough merge but HIV portfolio faces major challenges

GILEAD SCIENCES

Corporate strategy

The success of Truvada and Atripla is the foundation of Gilead's leadership in the HIV market

Moving forward, Gilead's bet on FDCs will cement the company's position as HIV market leader in the short- to mid-term future

HIV portfolio assessment

SWOT analysis for Gilead's HIV portfolio

VIIV HEALTHCARE

Corporate strategy

ViiV sets out to challenge Gilead's market dominance

HIV portfolio assessment

SWOT analysis for ViiV Healthcare's HIV portfolio

PORTFOLIO REVIEW OF OTHER LEADING HIV COMPANIES

Companies are looking to the market leaders to co-formulate their novel HIV candidates

Tibotec/Johnson & Johnson: US approval of Edurant further strengthens position in the HIV market

Bristol-Myers Squibb: Sustiva's patent expiry and a slim HIV pipeline will weaken HIV franchise

Merck & Co: setbacks in 2010 threaten competitiveness in the HIV market

Abbott: HIV position set to decline following Norvir's patent expiry in 2013/2014

Boehringer Ingelheim: strong reliance on Viramune and Aptivus as key setback for future growth in HIV

Roche: suspended HIV research in 2008

BIBLIOGRAPHY

Journal papers

Websites

Datamonitor reports

APPENDIX

Contributing experts

Conferences attended

Report methodology

To order this report:

Pathology Industry: Key Companies: HIV - Companies co-operate and co-formulate to stay competitive in a tight HIV market

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds The Outlook for Medical Devices in Brazil, Russia, India & China
2. Reportlinker Adds North America Acetic Acid Industry Outlook to 2015 - Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants
3. Reportlinker Adds U.S. Urinary Incontinence Devices
4. Reportlinker Adds U.S. Retinal Therapeutics Market
5. Reportlinker Adds Global CRO Market: Quantitative Assessment
6. Reportlinker Adds The Outlook for Medical Devices in North East Asia
7. Reportlinker Adds Global Microbiology Testing Market: US, Europe, Japan--Emerging Opportunities and Business Expansion Strategies for Suppliers
8. Reportlinker Adds Endovascular Surgical Interventions: Technology Market Penetration and Roadmapping
9. Reportlinker Adds Global Hemostasis Diagnostics Market: US, Europe, Japan--Emerging Opportunities and Business Expansion Strategies for Suppliers
10. Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers
11. Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... , , , WHEN: , , ... , , , LOCATION: , , , Online, with free registration ... PANELISTS:  , , , Frost & Sullivan,s Global Vice President of ... Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... witnessing an exceptional era. Several new demand spaces, such as innovative ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
Breaking Medicine News(10 mins):